Jump to any asset
849 assets, updated daily
As of September 26, 2026, Regeneron Pharmaceuticals, Inc. (REGN) trades at $788.04. CleaRank Financial AI rates it Buy with a fair value of $854.00, 8.4% above the current price. Wall Street's consensus target is $854.00 across 28 analysts. RSI at 35 is in neutral territory, and the price is above its 50-day average of $776.79.
Regeneron Pharmaceuticals, Inc. (REGN)
Regeneron Pharmaceuticals, Inc. NASDAQ
$788.04
-7.980 (-1.00%)
At close: Sep 25, 4:00 PM EDT
AI Analyst Consensus
68 / 100
Regeneron Pharmaceuticals, Inc. (REGN) is currently trading at $788.04, below its 20-day EMA but above its 50-day and 200-day moving averages ($776.79 and $735.69), indicating a mixed short-term technical picture. The company has demonstrated strong revenue growth of 16.7% and a strong profit margin of 27.87%, significantly outpacing the healthcare sector median of 8.1% revenue growth. Wall Street analysts maintain a consensus 'Buy' rating with a median price target of $854.00, suggesting an 8.4% upside potential. Despite a moderate sell signal from insider transactions, where $12.9 million in sales were recorded against no purchases, the overall fundamental and growth outlook remains positive. The company's strong performance in recent quarters, with EPS surprises consistently exceeding estimates, coupled with projected revenue growth of 18.00% for the current year, underpins the optimistic analyst sentiment. Key risks include potential competitive pressures and the valuation premium relative to sector averages.
REGN Price Analysis
Market Metrics
Open
$803.87
Day Range
$784.13 to $803.87
Prev Close
$796.02
Volume
592.1K
52-Week Range
$541.00 to $859.34
Market Cap
$81.13B
Peer Benchmarking
Valuation vs Sector (Healthcare)
Performance vs XLV
Sector Position Analysis
Trading at a notable discount to sector peers (-38%), which may indicate undervaluation or specific company headwinds.
REGN Financial Performance
Revenue vs. Earnings
Annual
Quarterly
Earnings Reality Check
Analysis: In the last 4 quarters, REGN beat estimates 3 times. The stock rose 2 times the next day. Price tends to react positively to beats.
REGN Analysis
Company's Health
4/5
12-Month Analyst Target
+8.37% Upside
Median of 28 analysts (12-month)
$854.00
AI Technical Analysis
Regeneron Pharmaceuticals, Inc. (REGN) is showing bearish momentum according to its RSI of 35.08, suggesting a potential pullback. The stock is trading below its 20-day EMA of $796.38 but remains above its 50-day SMA of $776.79 and its 200-day SMA of $735.69, indicating that the longer-term trend is still positive. Volume has been below average recently, with a 25.1% decrease compared to the average daily volume. The current price action suggests that the 50-day SMA is acting as support, while the 20-day EMA presents near-term resistance. Investors should monitor the RSI for signs of reversal from its oversold territory.
ProTips
- Monitor the RSI for a potential reversal from its current bearish reading as the stock approaches its 50-day SMA support level.
- Given the moderate insider selling, pay close attention to any future insider transactions for further clues on management's confidence.
- Consider the premium price-to-sales ratio relative to sector peers as a potential valuation risk, even with strong growth prospects.
Key Catalysts
Bullish
Strong Earnings Beat in June 2026 Quarter
Regeneron Pharmaceuticals (REGN) reported an EPS surprise of 39.96% for the quarter ending June 2026, significantly exceeding analyst expectations and driving positive stock movement.
Source: Company Earnings ReportBullish
Projected Revenue Growth of 18.00% for Current Year
Analysts forecast substantial revenue growth for REGN in the current year, indicating strong market demand for its products and services.
Source: Wall Street EstimatesBearish
Moderate Insider Selling Signal
Insiders have sold approximately $12.9 million worth of REGN stock with no reported purchases, indicating a moderate sell signal from management.
Source: Insider TransactionsNeutral
Trading Above Key Moving Averages
Regeneron Pharmaceuticals (REGN) is trading above its 50-day and 200-day moving averages ($776.79 and $735.69), suggesting underlying support despite short-term bearish momentum.
Source: Technical AnalysisMarket Outlook
The base case for Regeneron Pharmaceuticals, Inc. (REGN) anticipates continued growth driven by strong product demand and pipeline advancements, supporting a potential move towards its median analyst target price of $854.00 within the next 6-12 months. The company's projected revenue growth of 18.00% for the current year and an average of 10.5% over the next five years indicate sustained expansion. Upside catalysts could include successful clinical trial results for new therapies or stronger-than-expected earnings reports, potentially pushing the stock towards its higher price targets. Conversely, increased competition, regulatory hurdles, or a broader market downturn could pressure the stock, with downside risks potentially leading it towards the lower end of analyst targets or even its long-range projection downside of $454.10.
Key Statistics
| Market Cap | 81.13B |
|---|---|
| P/E Ratio | 19.70 |
| EPS (TTM) | 40.41 |
| Dividend Yield | 0.47% |
| 52 Week High | 859.34 |
| 52 Week Low | 541.00 |
Regeneron Pharmaceuticals, Inc. (REGN) trades at a P/E ratio of 19.70, which is below the healthcare sector median of 31.90, suggesting a potential valuation discount relative to peers. The company's price-to-sales ratio stands at 5.28, also below the sector median of 3.70, indicating it trades at a premium on a sales basis. However, its return on equity is a strong 14.04%, significantly higher than the sector average of 6.9%. With a profit margin of 27.87% and an operating margin of 33.11%, Regeneron demonstrates superior profitability compared to the sector. The company's debt-to-equity ratio is a healthy 0.09, indicating a strong balance sheet. These fundamentals, combined with strong revenue growth, support the current valuation despite the premium on a price-to-sales basis.
Earnings & Growth Analysis
Regeneron Pharmaceuticals, Inc. (REGN) delivered a strong earnings surprise of 39.96% in the quarter ending June 2026, with actual EPS of $14.29 significantly beating the estimate of $10.21, leading to a 3.29% price increase. This follows a pattern of positive earnings surprises in recent quarters, with the exception of the March 2026 quarter which missed estimates. The company is projected to achieve revenue growth of 21.00% year-over-year for the current quarter, indicating continued top-line expansion.
Key Risks
Regeneron Pharmaceuticals, Inc. (REGN) faces risks related to insider selling, with $12.9 million in sales recorded against no purchases, signaling a moderate sell signal from management. The stock's current valuation, particularly its price-to-sales ratio of 5.28, is at a premium compared to the sector average of 3.70. Additionally, while the RSI is currently bearish at 35.08, a sustained move below the 50-day SMA could indicate further downside pressure.
Technical Indicators
| RSI (14) | 35.08 |
|---|---|
| MACD | 1.88 |
| SMA 50 | 776.79 |
| SMA 200 | 735.69 |
RSI
Bearish
SMA Cross
Bullish
Price vs SMA
Bullish
MACD
Bullish
Golden Cross in effect with the 50-day SMA ($776.79) above the 200-day SMA ($735.69), price action is firmly bullish above key moving averages.
Market Correlations
How this stock moves relative to other assets
Based on 1 year of daily price data. Correlations may vary over different time periods.
S&P 500 (SPY)
+0.28
Weak correlation
Nasdaq 100 (QQQ)
+0.20
Weak correlation
Bitcoin (BTC)
+0.09
Weak correlation
Gold (XAU)
+0.06
Weak correlation
Check Custom Correlation
How does any other asset move with REGN? One year of daily closes, Pearson correlation.
Try
REGN Trade Plans
Specific entry, exit, and risk management levels
Select Your Trade Bias
Risk Tolerance
Conservative
2%
Aggressive
Portfolio Value
$
Position Size: Enter portfolio size →
Long entry pick an entry style
Conservative
$772.28
2% below current price (Pullback entry)
Lower risk, wait for pullback
Aggressive
$788.04
Buy at current price
Higher risk, immediate entry
Risk Management
STOP LOSS
$743.09
MAX LOSS
-3.8%
Volatility-Adjusted Stop Loss
Calculated based on RSI (35.1) and current market volatility
Profit Targets (Based on Conservative Entry)
TARGET 1
$810.89
+5% (Conservative)
+2.9% (Aggressive)
TARGET 2
$849.51
+10% (Conservative)
+7.8% (Aggressive)
TARGET 3
$888.12
+15% (Conservative)
+12.7% (Aggressive)
Consider scaling out: Take 50% profit at Target 1, 30% at Target 2, let 20% run to Target 3
Calculate Your Trade
Disclaimer
This AI-generated trade plan for REGN is for educational and informational purposes only and does not constitute financial advice. The analysis is based on historical data patterns and technical indicators which may not predict future results. Stock trading involves risk of loss. Verify all data independently and consult a qualified financial advisor. Generated on September 26, 2026.Growth of $10,000
A $10,000 investment in REGN in September 2016 would be worth about $19,500 today, compared with about $36,004 for the same investment in the S&P 500 benchmark.
Compare with Another Ticker
Monte Carlo Projection (10yr)
CleaRank's 10-year Monte Carlo simulation projects that a $10,000 investment in REGN today could grow to about $19,745 by 2036 in the base case, with a bull case near $72,582 and a bear case around $5,371. Projections are statistical simulations, not guarantees.
REGN Stock Price Prediction: 2030
CleaRank's simulation projects a price near $1,034 for REGN by 2030 in the base case, from $788 today (1.3x over 4 years). The downside path ends near $454. These are outcomes of a Monte Carlo simulation run on REGN's historical return distribution, not price targets, and they assume no dividends are reinvested.
| Year | Downside (10th pct) | Base case | Upside (90th pct) |
|---|---|---|---|
| 2027 | $559 | $844 | $1,273 |
| 2028 | $504 | $903 | $1,616 |
| 2029 | $474 | $966 | $1,972 |
| 2030 | $454 | $1,034 | $2,357 |
| 2031 | $441 | $1,107 | $2,780 |
| 2032 | $432 | $1,185 | $3,249 |
| 2033 | $427 | $1,269 | $3,770 |
| 2034 | $424 | $1,358 | $4,351 |
| 2035 | $423 | $1,454 | $4,998 |
| 2036 | $423 | $1,556 | $5,720 |
Method: 10,000 simulated price paths using REGN's historical volatility and drift, re-run daily. The base case is the median path; the two outer columns are the 10th and 90th percentile outcomes, which widen with time because uncertainty compounds. Simulations are not guarantees, and past volatility does not predict future returns. This is analysis, not investment advice.
People Also Watch
REGN Insider Trading Analysis
Bought
None
No open-market buys
Sold
$12.9M
15 Transactions
Insiders
19
Active Traders
Avg Transaction
$860.4K
Moderate size
| Date | Insider | Type | Shares | Value |
|---|---|---|---|---|
| May 29, 2020 | SANOFI SA
Beneficial Owner of more than 10% of a Class of Security
|
Sell | 22.8M | $11.6B |
| Aug 19, 2021 | SCHLEIFER LEONARD S
Chief Executive Officer
|
Sell | 210.0K | $136.6M |
| May 12, 2020 | SCHLEIFER LEONARD S
Chief Executive Officer
|
Sell | 150.9K | $85.9M |
| May 21, 2020 | VAGELOS P ROY
Chairman of the Board
|
Sell | 148.8K | $84.0M |
| Jun 9, 2020 | SANOFI SA
Beneficial Owner of more than 10% of a Class of Security
|
Sell | 120.2K | $71.8M |
| May 15, 2024 | YANCOPOULOS GEORGE D
President
|
Sell | 50.0K | $48.8M |
| May 16, 2024 | YANCOPOULOS GEORGE D
President
|
Sell | 50.0K | $48.6M |
| Jun 21, 2021 | YANCOPOULOS GEORGE D
President
|
Sell | 80.0K | $43.1M |
| Aug 24, 2020 | SING GEORGE LOUIS
Director
|
Sell | 61.0K | $36.9M |
| May 15, 2024 | SCHLEIFER LEONARD S
Chief Executive Officer
|
Sell | 35.9K | $35.2M |
Page 1 of 1
Frequently Asked Questions
What is Regeneron Pharmaceuticals' stock price forecast for 2030?
Regeneron Pharmaceuticals' (REGN) stock price forecast for 2030, based on Monte Carlo simulations, projects a base case of $1034.49, with a downside scenario of $454.10 and an upside scenario of $2356.70. These figures represent statistical outcomes, not guaranteed price targets.
Is Regeneron Pharmaceuticals stock a buy right now?
Regeneron Pharmaceuticals (REGN) currently holds a 'Buy' consensus rating from Wall Street analysts, supported by strong revenue growth and consistent earnings beats. The median analyst price target of $854.00 suggests an 8.4% upside from the current price of $788.04.
What are the key risks for Regeneron Pharmaceuticals?
Key risks for Regeneron Pharmaceuticals (REGN) include moderate insider selling totaling $12.9 million, a premium valuation on a price-to-sales basis compared to sector peers, and a bearish RSI indicating potential short-term weakness.
How does Regeneron Pharmaceuticals compare to its sector averages?
Regeneron Pharmaceuticals (REGN) demonstrates superior revenue growth (16.7% vs. 8.1% sector median) and profitability (ROE 14.04% vs. 6.9% sector median). While its P/E is lower than the sector median, its price-to-sales ratio is higher.
What was Regeneron Pharmaceuticals' most recent earnings performance?
In the quarter ending June 2026, Regeneron Pharmaceuticals (REGN) reported an EPS surprise of 39.96%, with actual EPS of $14.29 exceeding estimates of $10.21, leading to a 3.29% stock price increase.
What is Regeneron Pharmaceuticals' dividend yield?
Regeneron Pharmaceuticals (REGN) offers a dividend yield of approximately 0.47%, with a dividend rate of $3.70.
What is the overall sentiment from Wall Street analysts on REGN stock?
Wall Street sentiment for Regeneron Pharmaceuticals (REGN) is predominantly positive, with 28 analysts covering the stock. The consensus is 'Buy', comprising 4 'Strong Buy' ratings, 14 'Buy' ratings, and 9 'Hold' ratings, resulting in a Wall Street score of 68 out of 100.